Who Owns Evommune Stock?
NYSE: EVMNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 95.36%
- Held by insiders
- 2.77%
- Institutional holders
- 147
- Institutions 95.4%
- Insiders 2.8%
- Public and other 1.9%
Who owns Evommune stock?
Institutional investors own about 95.4% of Evommune's shares, spread across 147 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 2.77% of EVMN.
The largest institutional holders are Eqt Fund Management S.a R.l. (12.79%), RA Capital Management, L.P. (8.45%) and Point72 Asset Management, L.P. (5.89%). Together, the top 10 institutions control 50.7% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their EVMN positions and 0 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of EVMN
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Eqt Fund Management S.a R.l. | 5.29M | 12.79% | 0.0% |
| RA Capital Management, L.P. | 3.49M | 8.45% | 0.0% |
| Point72 Asset Management, L.P. | 2.43M | 5.89% | +69.6% |
| Pivotal bioVenture Partners Investment Advisor, LLC | 1.93M | 4.66% | 0.0% |
| Nan Fung Group Holdings Limited | 1.44M | 3.48% | 0.0% |
| Defilade Capital Management, L.P. | 1.43M | 3.46% | +80.4% |
| SymBiosis Capital Partners, LLC | 1.28M | 3.10% | 0.0% |
| Vestal Point Capital, LP | 1.25M | 3.02% | +25.0% |
| Baker Bros. Advisors, LP | 1.23M | 2.99% | +45.7% |
| Kynam Capital Management, LP | 1.20M | 2.90% | +100.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of EVMN
| Fund | Shares | % Held |
|---|---|---|
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 940.12K | 2.27% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 739.07K | 1.79% |
| T. Rowe Price New Horizons Fund, Inc. | 711.12K | 1.72% |
| American Century Mutual Funds, Inc.-Small Cap Growth Fund | 567.83K | 1.37% |
| JPMorgan Trust II-JPMorgan Small Cap Growth Fund | 554.36K | 1.34% |
| iShares Trust-iShares Russell 2000 ETF | 390.02K | 0.94% |
| T. Rowe Price Health Sciences Fund, Inc. | 346.63K | 0.84% |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 325.00K | 0.79% |
| TR PRICE-Price (T.Rowe) New Horizons Trust | 272.52K | 0.66% |
| T. ROWE PRICE QUANTITATIVE Mgmt Fd.S, INC.-T. Rowe Price Integrated U. | 258.20K | 0.62% |
Frequently asked questions
Who is the largest shareholder of Evommune?
Eqt Fund Management S.a R.l. is the largest institutional shareholder of EVMN, owning 12.79% of shares outstanding (5.29M shares) as of its latest 13F filing.
What percentage of Evommune is owned by institutions?
Institutions own about 95.4% of EVMN shares and 98.1% of the public float.
How much of Evommune do insiders own?
Insiders, such as officers and directors, own about 2.77% of EVMN shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.